CCR7 and melanoma: Validation using three independent bulk RNA-seq datasets (cBioPortal: DFCI melanoma; ENA: PRJEB23709; GEO: GSE91061) suggested that CCR7 was associated with favorable ICI response and improved survival, whereas MTRNR2L2 showed a tendency toward enrichment in non-responders and poorer outcomes.